Dexloxiglumide

Dexloxiglumide is a selective cholecystokinin type A (CCKA, also known as CCK1) receptor antagonist and the dextro isomeric form of loxiglumide. It was primarily developed for the treatment of gastrointestinal disorders, especially constipation-predominant irritable bowel syndrome (IBS-C) and gastroesophageal reflux disease (GERD). Dexloxiglumide works by inhibiting the CCKA receptor in the gastrointestinal tract, which increases gastric emptying and intestinal motility while modulating sensitivity to distension. Despite initial promise, clinical trials did not demonstrate significant efficacy over placebo for IBS-C, leading to discontinuation of development in some regions; however, further studies continued in Europe for IBS and GERD[2][3][4][5][6]. The drug is rapidly absorbed orally with moderate bioavailability due to first-pass metabolism. Its major metabolites are pharmacologically inactive; efficacy is attributed mainly to the parent compound.

Other names

dextro-loxiglumide